BRCA2 and breast cancer: Large international consortia, such as CIMBA [12] and ENIGMA [13], have conducted extensive analyses linking specific BRCA2 variants to the risk of BC and OC, providing strong evidence for the pathogenicity of certain variants through case–control studies, segregation analyses, and functional assays.